title: CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group.
abstract: The aim of this study was to test whether survival for patients with high-grade non-Hodgkin's lymphoma (NHL) can be improved with a non-cross-resistant regimen as compared to a CHOP-based regimen. This is a multicentre study comprising 325 adult patients, median age 58 years, with high-grade non-Hodgkin's lymphoma: patients of any age and performance status were eligible provided they were able to receive the drugs in the regimens. Patients were randomised to either B-CHOP-M (bleomycin, cyclophosphamide, doxorubicin, vincristine, prednisolone and methotrexate) or PEEC-M (methylprednisolone, vindesine, etoposide, chlorambucil and methotrexate) alternating with B-CHOP-M. At a median follow-up of 9 years, there was no significant difference in overall survival or disease-free survival between the two arms. Toxicities for the two regimens were equivalent. This study confirms that for relatively unselected patients with high-grade non-Hodgkin's lymphoma, an alternating multidrug regimen does not improve upon the results obtained with B-CHOP-M.
authors.affiliation: Department of Clinical Oncology, Western General Hospital, Edinburgh, U.K.
authors.forename: D A
authors.initials: DA
authors.lastname: Cameron
authors.forename: J M
authors.initials: JM
authors.lastname: White
authors.forename: S J
authors.initials: SJ
authors.lastname: Proctor
authors.forename: R J
authors.initials: RJ
authors.lastname: Prescott
authors.forename: R C
authors.initials: RC
authors.lastname: Leonard
authors.forename: B
authors.initials: B
authors.lastname: Angus
authors.forename: M K
authors.initials: MK
authors.lastname: Cook
authors.forename: P J
authors.initials: PJ
authors.lastname: Dawes
authors.forename: A A
authors.initials: AA
authors.lastname: Dawson
authors.forename: R G
authors.initials: RG
authors.lastname: Evans
authors.forename: M J
authors.initials: MJ
authors.lastname: Galloway
authors.forename: A L
authors.initials: AL
authors.lastname: Harris
authors.forename: A
authors.initials: A
authors.lastname: Heppleston
authors.forename: C H
authors.initials: CH
authors.lastname: Horne
authors.forename: A S
authors.initials: AS
authors.lastname: Krajewski
authors.forename: A L
authors.initials: AL
authors.lastname: Lennard
authors.forename: A M
authors.initials: AM
authors.lastname: Lessells
authors.forename: H H
authors.initials: HH
authors.lastname: Lucraft
authors.forename: J B
authors.initials: JB
authors.lastname: MacGillivray
authors.forename: M J
authors.initials: MJ
authors.lastname: Mackie
authors.forename: A C
authors.initials: AC
authors.lastname: Parker
authors.forename: J T
authors.initials: JT
authors.lastname: Roberts
authors.forename: P R
authors.initials: PR
authors.lastname: Taylor
authors.forename: W D
authors.initials: WD
authors.lastname: Thompson
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D002699:Chlorambucil / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001761:Bleomycin; D002699:Chlorambucil; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D014751:Vindesine; D008775:Methylprednisolone; D008727:Methotrexate